Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis
Michael E. Wechsler, Amy D. Klion, Pierluigi Paggiaro, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 10, pp. 2695-2709
Open Access | Times Cited: 143

Showing 1-25 of 143 citing articles:

Biologics and airway remodeling in severe asthma
Gilda Varricchi, Sebastian Ferri, J. Pepys, et al.
Allergy (2022) Vol. 77, Iss. 12, pp. 3538-3552
Open Access | Times Cited: 150
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management
William Shomali, Jason Gotlib
American Journal of Hematology (2024) Vol. 99, Iss. 5, pp. 946-968
Open Access | Times Cited: 16
ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis
Evan S. Dellon, Amanda B. Muir, David A. Katzka, et al.
The American Journal of Gastroenterology (2025) Vol. 120, Iss. 1, pp. 31-59
Closed Access | Times Cited: 7
Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Tyler Pitre, Dániel Lupas, Jasmine Mah, et al.
COPD Journal of Chronic Obstructive Pulmonary Disease (2025) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience
Cosimo Galletti, Federico Sireci, Giovanna Stilo, et al.
American Journal of Otolaryngology (2025) Vol. 46, Iss. 1, pp. 104597-104597
Open Access | Times Cited: 2
Two‐year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months
Rik Johannes Leonardus van der Lans, Josje Janna Otten, Gwijde Flavius Jacobus Petrus Maria Adriaensen, et al.
Allergy (2023) Vol. 78, Iss. 10, pp. 2684-2697
Open Access | Times Cited: 39
The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis
Matthew A. Rank, Derek K. Chu, Antonio Bognanni, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 2, pp. 386-398
Open Access | Times Cited: 38
Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study
B. Molina, Roberto Padoan, Maria Letizia Urban, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 12, pp. 1587-1593
Closed Access | Times Cited: 28
Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient
Linda Rogers, Miloš Jeseňák, Leif Bjermer, et al.
Respiratory Medicine (2023) Vol. 218, pp. 107414-107414
Open Access | Times Cited: 25
Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care
Cosimo Galletti, María Antonietta Barbieri, Francesco Ciodaro, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 630-630
Open Access | Times Cited: 24
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma
Leonard B. Bacharier, Ian Pavord, Jorge Máspero, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 1, pp. 101-110
Closed Access | Times Cited: 15
Dupilumab: Mechanism of action, clinical, and translational science
Marc R. McCann, Matthew P. Kosloski, Christine Xu, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 8
Open Access | Times Cited: 10
How I do it. Choosing the right biologic for the right patient with severe asthma
Simon Couillard, David J. Jackson, Ian Pavord, et al.
CHEST Journal (2024)
Open Access | Times Cited: 8
The Association of Inflammatory Indexes Derived from Peripheral Blood Cell Count and Clinical Signs with Response to Treatment with Dupilumab in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
Lingzhao Zhang, Jiangshan Pi, Jinsong Wang, et al.
Journal of Inflammation Research (2025) Vol. Volume 18, pp. 271-282
Open Access | Times Cited: 1
Severe asthma clinical remission after biologic treatment with anti-IL4/IL13: A real-life experience
Andrea Portacci, Ilaria Iorillo, Vitaliano Nicola Quaranta, et al.
Respiratory Medicine (2023) Vol. 217, pp. 107348-107348
Closed Access | Times Cited: 21
Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience
Cosimo Galletti, Martina Ragusa, Federico Sireci, et al.
American Journal of Otolaryngology (2023) Vol. 45, Iss. 1, pp. 104106-104106
Open Access | Times Cited: 19
Dupilumab‐induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis
Fabio S. Ryser, Ayla Yalamanoglu, Alan Valaperti, et al.
Allergy (2023) Vol. 78, Iss. 10, pp. 2712-2723
Open Access | Times Cited: 18
Eosinophils—from cradle to grave
Miloš Jeseňák, Zuzana Diamant, Dagmar Simon, et al.
Allergy (2023) Vol. 78, Iss. 12, pp. 3077-3102
Open Access | Times Cited: 18
The Management of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With Biologics
A. Wautlet, Claus Bachert, Martin Desrosiers, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 9, pp. 2642-2651
Closed Access | Times Cited: 17
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence
Marco Caminati, Claudio Micheletto, Francesca Norelli, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 1-2, pp. 15-23
Closed Access | Times Cited: 7
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Diana Bernardo, Thomas Bieber, Tiago Torres
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 5, pp. 753-764
Open Access | Times Cited: 16
S3 guideline Atopic dermatitis: Part 2 ‐ Systemic treatment
Thomas Werfel, Annice Heratizadeh, Werner Aberer, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2023) Vol. 22, Iss. 2, pp. 307-320
Open Access | Times Cited: 16
Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results
Claus Bachert, Tanya M. Laidlaw, Seong Cho, et al.
Annals of Otology Rhinology & Laryngology (2023) Vol. 132, Iss. 12, pp. 1649-1661
Open Access | Times Cited: 14
HES and EGPA
Paneez Khoury, Praveen Akuthota, Namhee Kwon, et al.
Mayo Clinic Proceedings (2023) Vol. 98, Iss. 7, pp. 1054-1070
Open Access | Times Cited: 13
Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life
Antonella Loperfido, Andrea Ciofalo, Carlo Cavaliere, et al.
Journal of Immunology Research (2023) Vol. 2023, pp. 1-10
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top